SeattleGenetics.com - Developer of antibody-based therapies for cancer patients
Seattle Genetics Inc.
Seattle Genetics, Inc. is a biotechnology company that works in developing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
Programs
SGN-40 is a humanized antibody targeted to the CD40 antigen. A phase II single-agent clinical trial in diffuse large B-cell lymphoma and a phase Ib combination trial of SGN-40 plus Revlimid® (lenalidomide) are ongoing, with plans to initiate four additional clinical trials of SGN-40 in combination with chemotherapy or other targeted agents for the treatment of non-Hodgkin's lymphoma and multiple myeloma.
SGN-33 (lintuzumab) is a humanized antibody targeted to the CD33 antigen. A phase Ib clinical trial of SGN-33 in patients with AML or MDS is underway and a phase IIb trial in combination with cytarabine in AML.
SGN-35 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody linked to a derivative of the highly potent class of drugs called Auristatins using our proprietary ADC technology. SGN-35 is in a phase I clinical trial for CD30-positive hematologic malignancies, including Hodgkin lymphoma.
SGN-30 is an antibody targeted to the CD30 antigen and is currently in three NCI-sponsored clinical trials in combination with chemotherapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).
SGN-70 is a humanized antibody targeting the CD70 antigen, possesses potent effector function and direct cell-killing ability.
SGN-75 is an ADC comprising the SGN-70 antibody linked to an Auristatin derivative using ADC technology. This product candidate may have application in renal cell cancer, CD70-positive hematologic malignancies as well as autoimmune diseases.
- Anti-CD19 ADC
Anti-CD19 ADC targets the CD19 antigen, a pan-B cell marker expressed on many hematologic malignancies, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Seattle Genetice Inc. has a worldwide license agreement with Genentech to develop and commercialize SGN-40. Also the company has licensed the ADC technology to Genentech, CuraGen, Progenics, Bayer, MedImmune and PDL BioPharma. There is also an agreement with Agensys to jointly develop up to two ADC products.
Seattle Genetics has internal research programs directed towards evaluating novel tumor antigens and monoclonal antibodies, discovering new classes of cell-killing drugs, researching novel linker systems and genetically engineering antibody-drug linkage sites.
Address
- Seattle Genetics, Inc.
- 21823 - 30th Drive S.E.
- Bothell, WA 98021
Contact
- Tel: (425) 527-4000
- Fax: (425) 527-4001
- Email:
- Investor and Media Relations
- Tel: (425) 527-4160
- Fax: (425) 527-4161
- Email:
- Human Resources
- Telephone: (425) 527-4000
- Fax: (425) 527-4001
- Email:
- Clinical Affairs
- Tel: (425) 527-4000
- Fax: (425) 527-4309
- Email:
- Business Development
- Tel: (425) 527-4000
- Fax: (425) 527-4001
- Email:
People
- Clay B. Siegall, Ph.D. President and Chief Executive Officer
- Eric L. Dobmeier, Chief Business Officer
- Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer
- Todd E. Simpson, Chief Financial Officer
- Morris Z. Rosenberg, D.Sc., Sr. Vice President, Development
- Paul J. Carter, Ph.D., Vice President, Antibody Technologies
- Iqbal S. Grewal, Ph.D., Vice President, Preclinical Therapeutics
- Peter D. Senter, Ph.D. Vice President, Chemistry
- Jonathan Drachman, M.D., Senior Medical Director
- Eric Sievers, M.D., Senior Medical Director
News
- Seattle Genetics Announces Proposed Public Offering of Common Stock - 14 January 2008
- Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma - 7 January 2008
- Seattle Genetics to Present at the 26th Annual JPMorgan Healthcare Conference - 4 January 2008
Additional Information
Related Domains
External Links
- Stock: SGEN
- Alexa: SeattleGenetics.com
- WHOIS for SeattleGenetics.com
